TOPLINE:
Nearly four in every 1000 youths and five in every 1000 adults in the United States reported having type 1 diabetes (T1D) in the National Health Interview Survey (NHIS) from 2019 through 2022.
METHODOLOGY:
Analysis of the 2019-2022 cycles of the NHIS, a nationally representative study of the noninstitutionalized US population.Data were collected through in-person and telephone interviews, with response rates ranging from 47.8% to 59.1% for youths (aged TAKEAWAY:Among youths, the reported T1D prevalence per 1000 was 3.5, with the highest rates among those aged 10-17 years (5.0), males (4.0), Hispanic youths (3.5), and non-Hispanic White youths (3.9).Among adults, the reported prevalence per 1000 was 5.3, and it was highest among those aged 45-64 years (6.1) and ≥ 65 years (5.3), non-Hispanic Black adults (4.8), and non-Hispanic White adults (5.9).
IN PRACTICE:
“Consistent with the study results, emerging evidence suggests a high prevalence of [T1D] among middle-aged and older adults…There was also a substantial burden of [T1D] in racial and ethnic minority youths and adults…These patients have less access to care and state-of-the-art diabetes technology, contributing to disparities in glycemic control and complications. More data on barriers to care are needed to inform interventions that advance health equity in populations with [T1D].”
SOURCE:
The study was conducted by Michael Fang, PhD, and colleagues at the Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, and published as a research letter online on April 4, 2024, in JAMA.
LIMITATIONS:
Possible misclassification because autoantibodies were not measured.
Some subgroup estimates were imprecise due to small sample sizes.
The response rate was ~50%-60%.
DISCLOSURES:
The work was supported by the National Heart, Lung, and Blood Institute. Fang had no further disclosures.
>>> Read full article>>>
Copyright for syndicated content belongs to the linked Source : Medscape – https://www.medscape.com/viewarticle/one-every-200-us-adults-has-type-1-diabetes-2024a10006cw